Bristol-Myers Squibb said that the European Commission approved Sprycel, in combination with chemotherapy for the treatment of pediatric patients with certain cancers or leukemia. This is the second pediatric leukemia indication for Sprycel in Europe.
“We are proud that the approval by the European Commission brings children with Ph+ acute lymphoblastic leukemia a new treatment option, including a powder formulation developed as part of our commitment to addressing the unique needs of children with cancer,” said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb.